Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 170A is a small, conserved human transmembrane protein that localizes to the membranes of the endoplasmic reticulum (ER) and the nuclear envelope. It functions as a key regulator of ER and nuclear envelope morphogenesis by promoting the formation of ER sheets at the expense of tubular ER. TMEM170A concentration influences the morphology of both the ER and nuclear envelope—downregulation induces tubular ER and nuclear envelope expansion, while overexpression promotes ER sheet formation and can inhibit nuclear envelope expansion. TMEM170A interacts antagonistically with RTN4 (a reticulon family protein), balancing the shape of the ER and the organization of the nuclear envelope and nuclear pore complexes. While it is not currently known as a therapeutic target or implicated in specific diseases, its central role in maintaining ER and nuclear envelope architecture is critical for cellular homeostasis[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 170A (TMEM170A).